Table 6.
Multivariate logistic regression trend analysis: SP a -IPTp b doses (continuous variable) associated with outcomes of interest
| Adjusted model c | Trend prevalence ratio estimate (95% CI d ) | Trend p-value |
|---|---|---|
| Placental infectione | ||
| Paucigravid | 0.88 (0.77-1.04) | 0.13 |
| Multigravid | 0.94 (0.76-1.16) | 0.58 |
| Low birth weight (<2,500 g) | ||
| Paucigravid | 0.54 (0.33-0.90) | 0.02 |
| Multigravid | 0.63 (0.41-0.97) | 0.04 |
| Preterm (<37 weeks) | ||
| Paucigravid | 0.85 (0.62-1.17) | 0.32 |
| Multigravid | 0.48 (0.34-0.69) | <0.0001 |
| Composite birth outcomef | ||
| Paucigravid | 0.94 (0.77-1.15) | 0.56 |
| Multigravid | 0.66 (0.53-0.82) | <0.001 |
| Any infectiong | ||
| Paucigravid | 0.89 (0.77-1.03) | 0.13 |
| Multigravid | 0.95 (0.77-1.17) | 0.63 |
aSP = sulphadoxine pyrimethamine.
bIPTp = intermittent preventive treatment for malaria in pregnancy.
cModel adjusts for: Age group (<18, 18–35, >35), gravidity as an interaction term, sleeping under an ITN the last night at home, living in a home treated with IRS, urban, facility, delivered during the wet season, marital status.
dCI = 95% confidence interval.
ePlacental infection outcome: histopathology classes 1–4 vs class 5.
fComposite birth outcome defined as infants born with any of: LBW, SGA, or preterm.
gAny infection defined as pathology classes 1–4, blood smear positive (maternal, placental or cord blood).